挥发性有机化合物分析辅助粪便免疫化学检测结直肠癌的系统综述与荟萃分析
该系统综述与荟萃分析更新了FIT和VOC检测结直肠癌的诊断准确性数据,并评估两者联合在症状人群中排除结直肠癌的效能。FIT在10 µg/g粪便阈值下合并敏感度0.914、特异度0.783;VOC敏感度0.837、特异度0.803。在结直肠癌患病率5%人群中,FIT阴性后患癌概率0.5%,FIT和VOC均阴性后降至0.1%。
要点
- FIT(10 µg/g)合并敏感度0.914、特异度0.783,VOC敏感度0.837、特异度0.803。
- 患病率5%人群中,FIT阴性后患结直肠癌概率0.5%,FIT与VOC均阴性后0.1%。
- FIT或VOC任一阳性时,每8例结肠镜检查可识别1例结直肠癌。
核心结论
- 在FIT阴性的症状人群中,VOC可作为排除结直肠癌的良好检测手段。
- FIT与VOC均阴性时估计概率降低0.4%,在基层医疗中可为排除结直肠癌提供足够的安全网。
研究设计与样本
- 系统综述与荟萃分析,更新了FIT和VOC检测结直肠癌诊断准确性的系统综述。
- 采用双变量模型对敏感度和特异度进行荟萃分析。
- 使用Fagan列线图估计FIT与VOC联合的临床效用,以FIT阴性者的验后概率作为VOC的验前概率。
主要发现
- FIT在10 µg/g粪便阈值下检测结直肠癌的合并敏感度为0.914(95%CI 0.894-0.936),特异度为0.783(95%CI 0.850-0.696)。
- VOC检测结直肠癌的敏感度为0.837(95%CI 0.781-0.881),特异度为0.803(95%CI 0.870-0.712)。
- FIT和VOC的曲线下面积分别为0.926和0.885。
- 在结直肠癌患病率5%的人群中,FIT阴性后患结直肠癌的估计概率为0.5%,FIT和VOC均阴性后为0.1%。
- FIT或VOC任一阳性时,需结肠镜检查以识别1例结直肠癌的数量为8。
关键数值与推荐
- FIT检测结直肠癌的阈值设定为10 µg/g粪便。
- FIT阴性者的验后概率作为VOC检测的验前概率用于联合评估。
临床怎么用
- 在FIT阴性的症状人群中,可考虑加做VOC检测以进一步排除结直肠癌。
- FIT与VOC均阴性时结直肠癌估计概率降至0.1%,可为基层医疗排除结直肠癌提供安全网。
局限性
- 该联合策略的成本效益和临床准确性尚需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Faecal immunochemical test (FIT) is emerging as a valid test to rule-out the presence of colorectal cancer (CRC). However, the accuracy of FIT is dependent on the cut-off applied. An additional low-cost test could improve further detection of CRC. AIMS: To evaluate the efficacy of combined FIT and volatile organic compounds (VOC) in the detection of CRC within symptomatic populations. METHODS: Systematic reviews on the diagnostic accuracy of FIT and VOC, for the detection of CRC, were updated. Meta-analyses were performed adopting a bivariate model for sensitivity and specificity. Clinical utility of combined FIT and VOC was estimated using Fagan's nomogram. Post-test probability of FIT negatives was used as a pre-test probability for VOC. RESULTS: The pooled sensitivity and specificity of FIT at 10 µg/g faeces, for the detection of CRC, were 0.914 (95% confidence interval [CI] = 0.894-0.936) and 0.783 (CI = 0.850-0.696), respectively. For VOC, the sensitivity was 0.837 (CI = 0.781-0.881) and the specificity was 0.803 (CI = 0.870-0.712). The area under the curve for FIT and VOC were 0.926 and 0.885, respectively. In a population with 5% CRC prevalence, the estimated probability of having CRC following a negative FIT was 0.5% and following both negative FIT and VOC was 0.1%. CONCLUSIONS: In a FIT-negative symptomatic population, VOC can be a good test to rule-out the presence of CRC. The estimated probability reduction by 0.4% when both tests being negative offers adequate safety netting in primary care for the exclusion of CRC. The number needed to colonoscope to identify one CRC is eight if either FIT or VOC positive. Cost-effectiveness and clinical accuracy of this approach will need further evaluation.
引用
- Chandrapalan S, Bosch S, Cubiella J, et al. Systematic review with meta-analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer. Aliment Pharmacol Ther. 2021. PMID: 34004036. doi:10.1111/apt.16405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。